BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 1437154)

  • 1. Bone marrow-transforming activity of linker insertion mutants of Abelson murine leukemia virus.
    Hevezi P; Alin K; Rees-Jones R; Goff SP
    Oncogene; 1992 Nov; 7(11):2323-8. PubMed ID: 1437154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro transformation of murine pro-B and pre-B cells by v-mpl, a truncated form of a cytokine receptor.
    Fichelson S; Vigon I; Dusanter I; Charon M; Velu T; Baillou C; Gisselbrecht S; Lemoine FM
    J Immunol; 1995 Feb; 154(4):1577-86. PubMed ID: 7836743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming activity and tissue tropism of hybrid retroviral genomes containing portions of the v-abl and v-src oncogenes.
    Hevezi P; Alin K; Goff SP
    Oncogene; 1993 Sep; 8(9):2413-23. PubMed ID: 8361756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of chimeric Gag-Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C-terminal domain.
    Mysliwiec T; Perego R; Kruh GD
    Oncogene; 1996 Feb; 12(3):631-40. PubMed ID: 8637720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl.
    Jackson PK; Paskind M; Baltimore D
    Oncogene; 1993 Jul; 8(7):1943-56. PubMed ID: 8510937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transformation of bone marrow cells from E mu-myc transgenic mice by Abelson murine leukemia virus and Harvey murine sarcoma virus.
    Dyall-Smith D; Cory S
    Oncogene Res; 1988 May; 2(4):403-9. PubMed ID: 2840624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel mutation within the kinase domain of v-abl gene responsible for temperature-sensitive colony-forming ability in soft agar.
    Soma T; Tsukada S; Oka Y; Kishimoto T; Sugiyama H
    Virology; 1993 Apr; 193(2):967-70. PubMed ID: 8460498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multistage progression of Abelson virus-infected murine pre-B-cells to the tumorigenic state.
    Palumbo GJ; Ozanne BW; Kettman JR
    Cancer Res; 1990 Mar; 50(6):1917-23. PubMed ID: 2155061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transforming pathways activated by the v-Abl tyrosine kinase.
    Shore SK; Tantravahi RV; Reddy EP
    Oncogene; 2002 Dec; 21(56):8568-76. PubMed ID: 12476303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temperature-sensitive transformation by an Abelson virus mutant encoding an altered SH2 domain.
    Mainville CA; Parmar K; Unnikrishnan I; Gong L; Raffel GD; Rosenberg N
    J Virol; 2001 Feb; 75(4):1816-23. PubMed ID: 11160680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
    Katzav S
    Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insertional mutagenesis of the Abelson murine leukemia virus genome: identification of mutants with altered kinase activity and defective transformation ability.
    Rees-Jones RW; Goff SP
    J Virol; 1988 Mar; 62(3):978-86. PubMed ID: 2828693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substitution of the LTR of Abelson murine leukemia virus does not alter the cell type of virally induced tumors.
    Green PL; Kaehler DA; McKearn J; Risser R
    Oncogene; 1988 Jun; 2(6):585-92. PubMed ID: 2838788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus and cell requirements for Friend virus granulocytic leukemogenesis in long-term bone marrow cultures of NIH swiss [N:NIH(S)] mice.
    Greenberger JS; Newburger PE; Lipton JM; Moloney WC; Sakakeeny MA; Jackson PL
    J Natl Cancer Inst; 1980 Apr; 64(4):867-78. PubMed ID: 6928998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arrested development: understanding v-abl.
    Kerr LD
    Bioessays; 1994 Jul; 16(7):453-5. PubMed ID: 7945272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of v-Abl transformation by p53 and p19ARF.
    Cong F; Zou X; Hinrichs K; Calame K; Goff SP
    Oncogene; 1999 Dec; 18(54):7731-9. PubMed ID: 10618713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of flat revertants isolated from cells transformed by Abelson murine leukemia virus (Ab-MuLV).
    Oka T; Yutsudo M; Inoue H; Higuchi F; Hakura A
    J Cell Physiol; 1990 Dec; 145(3):428-33. PubMed ID: 1703165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in the rel-homology domain alter the biochemical properties of v-rel and render it transformation defective in chicken embryo fibroblasts.
    Morrison LE; Boehmelt G; Enrietto PJ
    Oncogene; 1992 Jun; 7(6):1137-47. PubMed ID: 1594245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A small molecule Abl kinase inhibitor induces differentiation of Abelson virus-transformed pre-B cell lines.
    Muljo SA; Schlissel MS
    Nat Immunol; 2003 Jan; 4(1):31-7. PubMed ID: 12469118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.